OBJECTIVES: The imidazoquinoline family of drugs are Toll-like receptor 7/8 agonists that have previously been used in the treatment of cutaneous leishmaniasis. Because of the hydrophobic nature of imidazoquinolines, they are traditionally not administered systemically for the treatment of visceral leishmaniasis. We formulated liposomal resiquimod, an imidazoquinoline, for the systemic treatment of visceral leishmaniasis. METHODS: By using lipid film hydration with extrusion, we encapsulated resiquimod in liposomes. These liposomes were then injected intravenously to treat BALB/c mice infected with Leishmania donovani. RESULTS: Treatment with liposomal resiquimod significantly decreased the parasite load in the liver, spleen and bone marrow. In addition, resiquimod treatment increased interferon-γ and interleukin-10 production in an antigen recall assay. Resiquimod was shown to be non-toxic in histology and in vitro culture experiments. CONCLUSIONS: FDA-approved resiquimod, in a liposomal formulation, displays promising results in treating visceral leishmaniasis.
OBJECTIVES: The imidazoquinoline family of drugs are Toll-like receptor 7/8 agonists that have previously been used in the treatment of cutaneous leishmaniasis. Because of the hydrophobic nature of imidazoquinolines, they are traditionally not administered systemically for the treatment of visceral leishmaniasis. We formulated liposomal resiquimod, an imidazoquinoline, for the systemic treatment of visceral leishmaniasis. METHODS: By using lipid film hydration with extrusion, we encapsulated resiquimod in liposomes. These liposomes were then injected intravenously to treat BALB/c mice infected with Leishmania donovani. RESULTS: Treatment with liposomal resiquimod significantly decreased the parasite load in the liver, spleen and bone marrow. In addition, resiquimod treatment increased interferon-γ and interleukin-10 production in an antigen recall assay. Resiquimod was shown to be non-toxic in histology and in vitro culture experiments. CONCLUSIONS: FDA-approved resiquimod, in a liposomal formulation, displays promising results in treating visceral leishmaniasis.
Entities:
Keywords:
drug delivery; imidazoquinoline; therapy; visceral
Authors: C Benjamin Naman; Anthony D Gromovsky; Cory M Vela; Joshua N Fletcher; Gaurav Gupta; Sanjay Varikuti; Xiaohua Zhu; Emilia M Zywot; Heebyung Chai; Karl A Werbovetz; Abhay R Satoskar; A Douglas Kinghorn Journal: J Nat Prod Date: 2016-02-23 Impact factor: 4.050
Authors: C Benjamin Naman; Gaurav Gupta; Sanjay Varikuti; Heebyung Chai; Raymond W Doskotch; Abhay R Satoskar; A Douglas Kinghorn Journal: J Nat Prod Date: 2015-01-28 Impact factor: 4.050
Authors: Felipe Francisco Tuon; Leticia Ramos Dantas; Regina Maia de Souza; Victoria Stadler Tasca Ribeiro; Valdir Sabbaga Amato Journal: Parasitol Res Date: 2022-09-16 Impact factor: 2.383
Authors: Noah Craft; Ron Birnbaum; Natalie Quanquin; Marie Crisel B Erfe; Cara Quant; Jacquelyn Haskell; Kevin W Bruhn Journal: Clin Vaccine Immunol Date: 2014-07-16
Authors: M A Collier; K J Peine; S Gautam; S Oghumu; S Varikuti; H Borteh; T L Papenfuss; A R Sataoskar; E M Bachelder; K M Ainslie Journal: Int J Pharm Date: 2016-01-05 Impact factor: 5.875
Authors: Hua Zhang; Wei-Lun Tang; Azadeh Kheirolomoom; Brett Z Fite; Bo Wu; Kenneth Lau; Mo Baikoghli; Marina Nura Raie; Spencer K Tumbale; Josquin Foiret; Elizabeth S Ingham; Lisa M Mahakian; Sarah M Tam; R Holland Cheng; Alexander D Borowsky; Katherine W Ferrara Journal: J Control Release Date: 2020-11-13 Impact factor: 9.776
Authors: Natasha Vinod; Duhyeong Hwang; Salma H Azam; Amanda E D Van Swearingen; Elizabeth Wayne; Sloane Christian Fussell; Marina Sokolsky-Papkov; Chad V Pecot; Alexander V Kabanov Journal: Sci Adv Date: 2020-06-17 Impact factor: 14.136